These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12697735)

  • 21. Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants.
    Chang SY; Lee KC; Ko SY; Ko HJ; Kang CY
    Int J Cancer; 2004 Aug; 111(1):86-95. PubMed ID: 15185348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The distinct role of CD4+ and CD8+ T-cells during the anti-tumour effects of targeted superantigens.
    Litton MJ; Dohlsten M; Rosendahl A; Ohlsson L; Søgaard M; Andersson J; Andersson U
    Br J Cancer; 1999 Sep; 81(2):359-66. PubMed ID: 10496366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-expression of Flt-3 ligand gene ablates tumor immunity elicited by HER-2/neu DNA vaccine in transgenic mice.
    Venanzi FM; Barucca A; Havas K; Capitani M; Provinciali M; Scotti S; Concetti A
    Vaccine; 2010 May; 28(22):3841-7. PubMed ID: 20350624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag.
    Felicetti P; Mennecozzi M; Barucca A; Montgomery S; Orlandi F; Manova K; Houghton AN; Gregor PD; Concetti A; Venanzi FM
    Cytotherapy; 2007; 9(1):23-34. PubMed ID: 18236207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma.
    Smorlesi A; Papalini F; Amici A; Orlando F; Pierpaoli S; Mancini C; Provinciali M
    Vaccine; 2006 Mar; 24(11):1766-75. PubMed ID: 16288939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector.
    Gallo P; Dharmapuri S; Nuzzo M; Maldini D; Iezzi M; Cavallo F; Musiani P; Forni G; Monaci P
    Int J Cancer; 2005 Jan; 113(1):67-77. PubMed ID: 15386429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells.
    Lindencrona JA; Preiss S; Kammertoens T; Schüler T; Piechocki M; Wei WZ; Seliger B; Blankenstein T; Kiessling R
    Int J Cancer; 2004 Mar; 109(2):259-64. PubMed ID: 14750178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
    Winter H; Hu HM; Urba WJ; Fox BA
    J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins.
    Quaglino E; Mastini C; Amici A; Marchini C; Iezzi M; Lanzardo S; De Giovanni C; Montani M; Lollini PL; Masucci G; Forni G; Cavallo F
    Cancer Res; 2010 Apr; 70(7):2604-12. PubMed ID: 20332241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor effect of new HER2 peptide vaccination based on B cell epitope.
    Miyako H; Kametani Y; Katano I; Ito R; Tsuda B; Furukawa A; Saito Y; Ishikawa D; Ogino K; Sasaki S; Imai K; Habu S; Makuuchi H; Tokuda Y
    Anticancer Res; 2011 Oct; 31(10):3361-8. PubMed ID: 21965747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER-2/neu as a target for cancer vaccines.
    Baxevanis CN; Voutsas IF; Gritzapis AD; Perez SA; Papamichail M
    Immunotherapy; 2010 Mar; 2(2):213-26. PubMed ID: 20635929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice.
    Quaglino E; Mastini C; Iezzi M; Forni G; Musiani P; Klapper LN; Hardy B; Cavallo F
    Vaccine; 2005 May; 23(25):3280-7. PubMed ID: 15837233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple roles of perforin in hampering ERBB-2 (Her-2/neu) carcinogenesis in transgenic male mice.
    Macagno M; Bandini S; Stramucci L; Quaglino E; Conti L; Balmas E; Smyth MJ; Lollini PL; Musiani P; Forni G; Iezzi M; Cavallo F
    J Immunol; 2014 Jun; 192(11):5434-41. PubMed ID: 24790144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen.
    Tüting T; Gambotto A; Robbins PD; Storkus WJ; DeLeo AB
    Gene Ther; 1999 Apr; 6(4):629-36. PubMed ID: 10476222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimetastatic activity of a preventive cancer vaccine.
    Nanni P; Nicoletti G; Palladini A; Croci S; Murgo A; Antognoli A; Landuzzi L; Fabbi M; Ferrini S; Musiani P; Iezzi M; De Giovanni C; Lollini PL
    Cancer Res; 2007 Nov; 67(22):11037-44. PubMed ID: 18006850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mesenchymal stromal cells expressing ErbB-2/neu elicit protective antibreast tumor immunity in vivo, which is paradoxically suppressed by IFN-gamma and tumor necrosis factor-alpha priming.
    Romieu-Mourez R; François M; Abate A; Boivin MN; Birman E; Bailey D; Bramson JL; Forner K; Young YK; Medin JA; Galipeau J
    Cancer Res; 2010 Oct; 70(20):7742-7. PubMed ID: 20924101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cytotoxic activity of spleen lymphocytes in BALB/c mice immunized by HSP110-HER2/neu ICD].
    Han D; Xu H; Yan WQ
    Zhonghua Zhong Liu Za Zhi; 2012 Jan; 34(1):11-4. PubMed ID: 22490848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors.
    Triulzi C; Vertuani S; Curcio C; Antognoli A; Seibt J; Akusjärvi G; Wei WZ; Cavallo F; Kiessling R
    Cancer Res; 2010 Oct; 70(19):7431-41. PubMed ID: 20823150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
    Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
    Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the gamma-chain from Fc(epsilon) RI.
    Mamalaki A; Gritzapis AD; Kretsovali A; Belimezi M; Papamatheakis J; Perez SA; Papamichail M; Baxevanis CN
    Cancer Immunol Immunother; 2003 Aug; 52(8):513-22. PubMed ID: 12715240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.